• Search
  • Helpdesk
  • Sales contact
Get your demo

How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

CSR
Last updated: October 24, 2025

In 2020, we implemented a carbon neutral program for all our clinical trials.
Our goal? To reduce project CO2 emissions without impacting cost, quality or timelines.

Download the infographic
Ask for more information
Follow us on social media
Subscribe to our newsletter
You may also like

Better Raters,Smarter eCOA,Stronger Data

Strengthening Endpoint Reliability: An Interview with Estelle Haenel, Chief Medical...

Kayentis and RWS join forces to improve data confidence in...

What if eCOA could elevate your next rare disease trial?

Elevating rare disease clinical trials through eCOA – From patient...

Overcoming rare disease trial challenges: the strategic impact of eCOA

About the author
Picture of Marc Chaperon

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.
Meet us at the following events

PCMG 2026

JUNE 15-17 2026 • Berlin, Germany
Meet our colleagues Chris BARDEN and Andrea MURISON at PCMG.  Schedule a meeting

6th Annual Clinical Trial Innovation Summit

24 JUNE 2026 • BASEL, CH

DPHARM 2026

SEPT 15-16 2026 • Boston, MA, USA
Booth #306  
Kayentis and RWS join forces to improve data confidence in neuroscience clinical trials
Combining best-in-class eCOA technology with expert rater training to reduce variability and strengthen clinical outcomes data in CNS and other complex disorder clinical trials.
  • Read the full press release